The DC vaccine presents neoantigen peptides with costimulation (CD80/86 engaging CD28) to activate and expand tumor-specific CD8 T cells, which then kill neoantigen-bearing tumor cells via perforin/granzyme or Fas–FasL. CD28+ T cells themselves are not targeted or killed.